Scalability of the iPSC technology for future drug discovery & therapy – Workshop

By | Pluripotent stem cells and engineered cells

The EBiSC consortium invites you to the Workshop “Scalability of the iPSC technology for future drug discovery & therapy” on 2-3 November 2017 at Fraunhofer-Forum in Berlin. The workshop aims at disseminating the learning from the establishment of the European Bank for induced Pluripotent Stem Cells (www.ebisc.eu) and address perspectives on stem cell applications over the next five years.

Read More

Regulator ready’ stem cell lines now available for clinical development

By | Pluripotent stem cells and engineered cells

The UK Stem Cell Bank (UKSCB) at the National Institute for Biological Standards and Control (NIBSC) is releasing its first stem cell lines suitable for development into novel cell-based medicines to researchers wishing to bring new and innovative therapies to clinical trial.

The stem cell lines are produced and quality-controlled under European regulation and are therefore suitable for use as starting materials in manufacturing therapies for clinical trials, saving researchers precious time and effort.

Read More